Earn CME credit for this activity: https://www.naccme.com/program/2018-802-03
This on-demand activity examines the implications of BRCA mutational status, BRCAness, synthetic lethality, and within-class differences in the mechanisms of action, efficacy and safety, and indications of available and emerging PARP inhibitors for optimal ovarian cancer pathway integration.
© 2018 NACCME, an HMP Company